Baxter International in Deerfield, agreed to acquire two hemostat and sealant products from British-based Mallinckrodt Pharmaceuticals: Recothrom, the first and only standalone recombinant thrombin, and Preveleak Surgical Sealant for use in vascular reconstruction.
Here are five things to know about the proposed acquisitions:
- Thrombin is a blood coagulation agent that has been used to address intraoperative bleeding in over an estimated one million patients per year in the United States.
- Recothrom is the only topical hemostat that comes from recombinant DNA to be approved in the United States and Canada, and it can be used in pediatric and adult patients with or without antibodies to bovine-derived thrombin.
- Preveleak is a surgical sealant designed to suture holes formed during surgical circulatory system repair and to reinforce severed connections between blood vessels. Preveleak is approved for use in the EU and United States.
- In the 12 months before Sept. 27, 2017, sales of Recothrom and Preveleak totaled approximately $56 million.
- Baxter will acquire the products for an upfront payment of about $153 million and potential future contingent payments.
More articles on healthcare supply chain:
Allscripts to acquire Practice Fusion for $100M: 5 things to know
McKesson completes $735M acquisition of CrossroadsRx: 4 things to know
Medline awarded OneBlood distribution agreement — 3 insights